Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$208.0 million.

  • Spyre Therapeutics' Net Income towards Common Stockholders rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
  • Per Spyre Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$208.0 million for FY2024, which was up 38.60% from -$338.8 million recorded in FY2023.
  • Spyre Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$65.8 million during FY2021, with a 5-year trough of -$338.8 million in FY2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$208.0 million (2024), whereas its average is -$210.2 million.
  • Per our database at Business Quant, Spyre Therapeutics' Net Income towards Common Stockholders tumbled by 304.21% in 2023 and then skyrocketed by 38.60% in 2024.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Net Income towards Common Stockholders stood at -$80.9 million in 2020, then climbed by 18.66% to -$65.8 million in 2021, then dropped by 27.38% to -$83.8 million in 2022, then tumbled by 304.21% to -$338.8 million in 2023, then skyrocketed by 38.60% to -$208.0 million in 2024.